enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside
Analyst estimates for enGene Therapeutics Inc. show its average 12-month price target was cut from $3.50 to $3.43, with a range of $2 to $5 per share. Based on the Aug. 14 close, the target implies about 102% upside. The consensus rating remains “Hold” with 4 Buys, 5 Holds, and 1 Sell.
How this was made
The 30-second read
Why it matters
This is primarily a sentiment/valuation update from analysts, not a new fundamental disclosure. The implied upside is based on the Aug. 14 closing price, but the consensus rating remains Hold.
Market read
Traders may treat this as a mild valuation reset rather than a standalone catalyst, given the unchanged Hold rating and lack of new operational details.
What to watch
Price-target changes may lag new fundamentals; traders should verify whether any recent clinical, regulatory, or financing events occurred around Aug. 14 that are not captured in this brief.
Background
The piece summarizes FactSet-derived analyst estimates: average 12-month price target, target range, and consensus rating mix.
Ticker impact
enGene Therapeutics’ average analyst price target fell from $3.50 to $3.43, with a $2 to $5 range and a Hold consensus.
Likely modest downside bias or limited upside follow-through, unless new fundamental catalysts emerge beyond this PT update.
The only disclosed change is the average target level; the consensus rating remains Hold, and no new company-specific operational or clinical datapoint is provided.
Market effects
Minimal, as this is a single-name analyst target revision without sector-wide regulatory, trial, or reimbursement updates.
None indicated.
None indicated.
Counterpoint
A lower average target can still coexist with upside if the distribution includes higher outliers (top forecast $5) and the stock is already priced for pessimism.
Key entities
- public_companyenGene Therapeutics Inc.
Subject of the article, with an average 12-month price target cut to $3.43 and Hold consensus.
